"The difficulty we faced at that time is that pricing and reimbursement issues had never been discussed as part of a trade agreement," said BIO's Joseph Damond. …
Latest Video
New Stories
-
A perspective that rightly belongs in a time capsule from the 1990s
October 23, 2025 - - Latest News -
Global focus intensifies as AusBiotech strengthens trade, partnerships and international engagement
October 23, 2025 - - Australian Biotech -
Queensland resources sector backs prevention-first health push to boost workforce productivity
October 23, 2025 - - Latest News -
Omico appoints Richard Vines as new Chair as it strengthens national precision oncology agenda
October 23, 2025 - - Latest News -
New Zealand identified as a ‘major outlier’ in OECD medicines investment
October 23, 2025 - - BioPharma -
Island Pharmaceuticals secures FDA response date for Galidesivir approval pathway
October 23, 2025 - - Australian Biotech -
Noxopharm granted first US patent for Sofra immune-modulation platform
October 23, 2025 - - Australian Biotech